Physician profile
Kari Murphy
NPI 1336548049
$4,695.07
in general payments reported to CMS, 2019-2025
12 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $428 · 2023: $1,378 · 2024: $1,660 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Education: $4.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,152.76 |
| Education | $4.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,056.03 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $615.47 | 2023-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $560.82 | 2023-2025 | Sublocade, Perseris |
| Abbvie INC. | $511.93 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $441.30 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $394.94 | 2023-2025 | Auvelity |
| Alkermes, INC. | $370.36 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $236.29 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $214.90 | 2025 | Fanapt |
| Lundbeck LLC | $135.93 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $103.95 | 2024-2025 | Uzedy |
| Noven Therapeutics, LLC | $53.15 | 2023 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.